EMA, HTA Bodies & Payers Explore Common Ground On Use Of RWE
Executive Summary
A technical workshop is planned for later this year to identify common “use cases” for real-world evidence that are important to the European Medicines Agency, health technology assessment bodies and payers.
You may also be interested in...
EMA Makes Progress On Real-World Evidence ‘Use Cases’ With HTA Bodies & Payers
The European Medicines Agency is looking at how it can generate real-world evidence on multiple myeloma and non-small cell lung cancer using its new DARWIN EU platform so that the outcomes can also be of use for health technology assessment bodies and payers.
High Ambitions For EU DARWIN Platform After Delivery Of First RWE Studies
Within one year of its establishment, DARWIN EU has started reaping benefits for EU drug regulators commissioning studies using real-world data to better understand diseases, populations and the uses and effects of medicines. The studies can be performed faster, cheaper and at increased capacity.
RWE Studies To Hit 100+ Per Year In Europe By 2025
The EU’s big data steering group has laid out some ambitious proposals for integrating real-world evidence into regulatory decision making, as well as plans for ongoing engagement on the use and analysis of RWE with industry and other stakeholders.